Spine and Non-spine Bone Metastases - Current Controversies and Future Direction.
Bone metastases
bone-modifying agents
bone-targeted radionuclides
palliative radiotherapy
surgery
Journal
Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
08
04
2020
revised:
21
05
2020
accepted:
10
07
2020
pubmed:
5
8
2020
medline:
29
5
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
Bone is a common site of metastases in advanced cancers. The main symptom is pain, which increases morbidity and reduces quality of life. The treatment of bone metastases needs a multidisciplinary approach, with the main aim of relieving pain and improving quality of life. Apart from systemic anticancer therapy (hormonal therapy, chemotherapy or immunotherapy), there are several therapeutic options available to achieve palliation, including analgesics, surgery, local radiotherapy, bone-seeking radioisotopes and bone-modifying agents. Long-term use of non-steroidal analgesics and opiates is associated with significant side-effects, and tachyphylaxis. Radiotherapy is effective mainly in localised disease sites. Bone-targeting radionuclides are useful in patients with multiple metastatic lesions. Bone-modifying agents are beneficial in reducing skeletal-related events. This overview focuses on the role of surgery, including minimally invasive treatments, conventional radiotherapy in spinal and non-spinal bone metastases, bone-targeting radionuclides and bone-modifying agents in achieving palliation. We present the clinical data and their associated toxicity. Recent advances are also discussed.
Identifiants
pubmed: 32747153
pii: S0936-6555(20)30292-2
doi: 10.1016/j.clon.2020.07.010
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
728-744Informations de copyright
Copyright © 2020 The Royal College of Radiologists. All rights reserved.